AOP Health and VRG Therapeutics partner on immunology program

May 13, 2026

AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.

Today's news in brief

BioWorld

BioWorld briefs for June 1, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Healthy (left) vs. cancerous bone marrow

BMS’ mezigdomide doubles PFS in multiple myeloma

BioWorld

Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...

ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

BioWorld

Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...